NorthX Biologics, a leading Nordic biopharmaceutical Contract, Development and Manufacturing Organization, is pleased to announce a significant growth investment from Signet Healthcare Partners, a U.S.-based healthcare private equity firm with deep expertise in pharmaceutical services. This strategic partnership will enable NorthX Biologics to accelerate its expansion plans, including enhancing facilities, broadening service lines, and extending U.S. commercial reach.
Health Technology Insights: Altera’s Integrated Operating Theater System Launches at Latrobe Regional Health
NorthX Biologics provides a wide range of complex biologics manufacturing services, including recombinant proteins, viral vaccines and cell therapies. It serves a global customer base of biopharmaceutical and biotech companies, from early development through commercial GMP manufacturing.
The investment was made through a new issue of shares. Following the transaction, James Gale, Managing Director at Signet Healthcare Partners, will join the NorthX Biologics Board of Directors.
Health Technology Insights: Jill Thompson and Harold Kisner Join CLEU Diagnostics Advisory Board
“We are delighted to welcome Signet Healthcare Partners as a shareholder. With their significant experience in pharma services, they are an excellent complement to NorthX Biologics and are well positioned to support our journey,” said Janet Hoogstraate, Chief Executive Officer of NorthX Biologics.
“With Signet Healthcare Partners, we gain another strong owner who brings extensive experience in developing fast-growing biopharmaceutical companies. I look forward to welcoming James to the board and working together with Signet to continue the global expansion of NorthX Biologics,” added Thomas Eldered, Chairman of NorthX Biologics and Flerie.
“We are excited to invest in NorthX Biologics to support its ambitious growth strategy. NorthX Biologics’ differentiated capabilities across microbial and mammalian manufacturing systems, nucleic acids, advanced therapies and aseptic fill-finish are a strong match with the evolving needs of the global biopharma market. Together with Flerie, as a significant shareholder in NorthX Biologics, we look forward to helping accelerate NorthX Biologics commercial strategy while supporting its broader global vision,” said James Gale, Managing Director at Signet Healthcare Partners.
Flerie remains the majority shareholder following the transaction. Terms were not disclosed. Setterwalls served as legal advisor to NorthX Biologics. Advokatfirman Delphi and Sheppard, Mullin, Richter & Hampton served as legal advisors to Signet.
Health Technology Insights: TruBridge Enhances Community Healthcare with Microsoft Collaboration
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – businesswire
